Brain cancer vaccines:

A primary brain tumor is a group
(mass) of abnormal cells that start in
the brain.
A metastatic brain tumor is brain
cancer that has spread from another
part of the body.




BRAIN CANCER VACCINE ICT-107
TESTED IN PHASE 2
In January 2012 a national clinical trial
testing the efficacy of a novel brain
tumor vaccine has begun at Wake
Forest Baptist Medical Center, the only
facility in the Southeast to participate.
The vaccine will be tested in patients
with newly diagnosed glioblastoma
multiforme (GBM), the most aggressive
and highest grade malignant glioma.
Wake Forest Baptist will treat a
minimum of 25 patients in this
randomized, placebo-controlled phase
II clinical trial of ICT-107.

A total of 20 sites across the country
are participating in the trial to test the
safety and efficacy of this novel cancer
vaccine.

All patients enrolled in the study will
receive the current standard treatment
for GBM, which includes surgery
followed by radiation and
chemotherapy. Two thirds of the
participants will then also get the
experimental vaccine treatment, which
will be administered in the post
radiation phase of treatment, while the
others will get a “dummy,” or placebo
vaccine in addition to standard therapy.

The approach with this particular
vaccine is unique, Lesser added,
because it is targeting the antigens or
proteins that are present on glioma
stem cells, whereas other treatment
approaches mostly target
differentiated tumor cells.

See   results below  from Phase 1:




IMMUNOCELLULAR THERAPEUTICS
ANNOUNCES 55% OVERALL
SURVIVAL AT 3 YEARS FROM PHASE
1 STUDY IN GLIOBLASTOMA
In September 2011 ImmunoCellular
Therapeutics, Ltd.  announced
updated long-term data from a Phase I
clinical trial of ICT-107, the Company's
lead cancer vaccine candidate for the
treatment of glioblastoma multiforme
(GBM), the most common and
aggressive form of brain cancer.

Three-year overall survival is 55%
compared to 16% based on historical
standard of care (SOC). The data
show that 38% of newly diagnosed
patients who received ICT-107
continue to show no tumor recurrence
after three years, compared to the
historic disease-free survival rate of
6% with current standard of care. Out
of these patients, 19% remain disease-
free after more than four years.

The Phase I clinical study was
conducted in 16 newly diagnosed
glioblastoma patients, who received
three injections of ICT-107 in addition
to standard treatment with surgery,
radiation and chemotherapy. The
company has previously reported a
two-year survival rate of 80.2% in
study patients, which compares
favorably to the historic median two-
year survival rate of 26.5% with SOC
alone. No serious adverse events have
been reported and minor side effects
have been limited to fatigue, skin rash
and pruritis.



CDX-110 IS BRAIN VACCINE FOR
GLIOBLASTOOMA MULTIFORME
Celldex Therapeutics Inc. and partner
Pfizer Inc. are developing  cancer
vaccine CDX-110 for  newly diagnosed
glioblastoma multiforme in early stage
clinical trials.

Early stage clinical trial data showed
that the vaccine CDX-110  succeeded
to prolong the life of 70% of  patients
afflicted with glioblastoma multiforme
(GBM) – the most deadly form of brain
cancer — without worsening their
symptoms.
CDX-110 is an immunotherapy that
targets the tumor specific molecule
called EGFRvIII.
CDX-110 is designed to activate the
patient’s immune response against
tumor cells specifically expressing the
EGFRvIII mutation.